Matching placebo

Phase 3

Novartis

Matching placebo is one of 115 therapeutic programs targeting Aortic Stenosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[2][1]

Indication

Aortic StenosisRecruiting

Biliary AtresiaTerminated

MigraineRecruiting

Chronic Inducible UrticariaRecruiting

Breast NeoplasmsRecruiting

Aortic StenosisPhase 2

Recruiting

Biliary AtresiaPreclinical

Terminated

MigrainePhase 3

Recruiting

Chronic Inducible UrticariaPhase 3

Recruiting

Breast NeoplasmsPhase 3

Recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

Matching placebo

Novartis

Phase 3

1 2

Aimovig

Amgen

Preclinical

33 3

Emgality

Eli Lilly

Preclinical

19 4

Vyepti

Lundbeck

Preclinical

12 5

Bayer Aspirin

Bayer

Preclinical

2 6

Savella

AbbVie

Preclinical

2 7

Botox

RRevance Therapeutics, Inc.

Preclinical

9 8

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 9

Viagra

VViatris Specialty LLC

Preclinical

2 10

Pristiq

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Chronic Inducible Urticaria

NCT07266402

Q1 2029

Phase 3Recruiting

Migraine

NCT04649242

Q1 2030

Phase 2Recruiting

Aortic Stenosis

NCT05646381

Q3 2030

Phase 3Recruiting

Breast Neoplasms

NCT07173751

Clinical

Trials by Indication[1]

Migraine1 trial

Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT04649242·2,100 enrolled

Biliary Atresia1 trial

A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Obeticholic Acid Compared to Placebo in Pediatric Subjects With Biliary Atresia, Post-hepatoportoenterostomy

Terminated·IIntercept Pharmaceuticals·Preclinical·NCT06121375·28 enrolled

Chronic Inducible Urticaria1 trial

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study of Barzolvolimab in Participants With Cold Induced Urticaria and Symptomatic Dermographism (EMBARQ-COLDU and SD)

Recruiting·CCelldex Therapeutics·Phase 3·NCT07266402·240 enrolled

Breast Neoplasms1 trial

A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease

Recruiting· BioNTech logo

BioNTech·Phase 3·NCT07173751·558 enrolled

Aortic Stenosis1 trial

A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]

Recruiting· Novartis logo

Novartis·Phase 2·NCT05646381·502 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Matching placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Matching placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Novartis

Matching placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q1 2029

Q1 2030

Q3 2030

Trials by Indication[1]

Migraine1 trial

Biliary Atresia1 trial

Chronic Inducible Urticaria1 trial

Breast Neoplasms1 trial

Aortic Stenosis1 trial

References

Drug Info

Quick Facts

Related News